• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Neuroscience

The following trials provide information to treat various types of disease of the brain and the central and local nervous systems, both for ongoing and completed clinical trials.  For more information on this therapy area please click here.

There are a number of ways to help you find trial information.  By using these filters you can find (i) recruiting status, (ii) therapy area, (iii) product and/or (iv) phase of drug development.  You can use one or all filters to identify your specific needs.

When a trial completes the results are reported here no later than one year after completion – this is why you may sometimes find that a Report is unavailable when you are searching through ‘closed’ trials.

  • Expand All
  • Collapse All
  • Pages
  • Previous
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • Next
  • collapse A Phase I, Randomised, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1386 in Healthy Caucasian young and elderly subjects after oral multiple doses.
  • collapse A Phase I, Single-Centre, Randomised, Open-Label, Five-Way Cross-Over Formulation- and Food-Effect Study in Healthy Volunteers to Assess the Pharmacokinetics of AZD1386 after Single Doses of Two Oral Solid Formulations and an Oral Solution
  • collapse Evaluating Subjective Well-being in Schizophrenic Patients Treated With quetiapine and Other Atypical Antipsychotics
  • collapse A Randomized, Open-label Trial to Evaluate the Pharmacokinetics of Extended-Release (XR) Quetiapine Fumarate 300 mg, 600 mg and 800 mg in Chinese schizophrenic patients
  • collapse A Randomised, Double-Blind, Parallel Group Multicentre Trial to Compare the Efficacy and Safety of Zolmitriptan 2.5 mg, Zolmitriptan 5.0 mg and Sumatriptan 50 mg in the Treatment of Migraine Headache (311CIL/0070 [ZEUS]) (6-Attack Analysis).
  • collapse A Multicenter, Double-blind, Randomized, Parallel-group, Placebocontrolled, Phase III Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Sustained-release as Monotherapy in Adult Patients with Acute Bipolar Mania
  • collapse A Multicenter, Double-blind, Randomized, Parallel-group, Placebocontrolled, Phase III Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Sustained-Release as Monotherapy in Adult Patients With Acute Bipolar Depression
  • collapse A Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double- Blind, Phase III Study to Compare the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) versus Placebo as Adjunct Therapy with Mood Stabilizers (Lithium or Divalproex) for the Treatment of Alcohol Dependence in Patients with Bipolar I Disorder.
  • collapse The Effect of the Atypical Antipsychotic Quetiapine in the Treatment of Postpartum Depressive Disorders with or without Psychotic Symptoms
  • collapse An open, randomised, parallel, three treatment groups, multicentre, phase IV study - in real life - to compare the change in social outcome of quetiapine fumarate (Seroquel) combined with Cognitive Remediation Therapy to conventional treatment in patients
  • Pages
  • Previous
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • Next
  • Expand All
  • Collapse All

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013